Business Context and Reporting Period
This Form 8-K was filed by Aeglea BioTherapeutics, Inc. on July 13, 2018. The report discloses a corporate governance event: the appointment of a new director to the Board of Directors. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to the compensation package for the newly appointed director:
- Annual Cash Retainer: $37,500
- Stock Option Grant: 36,800 shares
- Exercise Price: $8.78 per share
- Vesting Schedule: Monthly over three years
Material Changes
The material change reported is the appointment of Bryan Lawlis as a Class III director, effective July 13, 2018. There are no reported changes to the company's financial position or operations in this filing.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of specific risks or contingencies beyond the standard disclosure that no undisclosed arrangements influenced the director's appointment. The company confirmed that Dr. Lawlis has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the total number of outstanding shares and the dilution impact of the 36,800 new options granted.
- Confirm the current stock price relative to the $8.78 exercise price to assess the intrinsic value of the grant.
- Review the company's existing compensation policy for non-employee directors to ensure the $37,500 retainer aligns with peer standards.
- Check subsequent filings for any changes to the Board composition or additional compensation arrangements.